Litcius/Paper detail

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang, Shukui Qin, Kensei Yamaguchi, Inho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Hacı Mehmet Türk, Alexandra Teixeira, Christophe Borg, Erika Hitre, Adrian Udrea, Giovanni Gerardo Cardellino, Raquel Guardeño Sanchez, Helen Collins, Siddhartha Mitra, Yingsi Yang, Daniel V.T. Catenacci, Keun‐Wook Lee

2022The Lancet Oncology222 citationsDOI

Topics & Concepts

Clinical endpointInternal medicineMedicineGastroenterologyOxaliplatinPlaceboPhases of clinical researchAdenocarcinomaClinical trialSurgeryCancerColorectal cancerPathologyAlternative medicineFibroblast Growth Factor ResearchEsophageal Cancer Research and TreatmentGastrointestinal Tumor Research and Treatment
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study | Litcius